EA201691258A1 - Ангиотензин ii самостоятельно или в комбинации для лечения гипотензии - Google Patents

Ангиотензин ii самостоятельно или в комбинации для лечения гипотензии

Info

Publication number
EA201691258A1
EA201691258A1 EA201691258A EA201691258A EA201691258A1 EA 201691258 A1 EA201691258 A1 EA 201691258A1 EA 201691258 A EA201691258 A EA 201691258A EA 201691258 A EA201691258 A EA 201691258A EA 201691258 A1 EA201691258 A1 EA 201691258A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dose
norepinephrine
treatment
hypotensia
angiotenzin
Prior art date
Application number
EA201691258A
Other languages
English (en)
Other versions
EA037823B1 (ru
Inventor
Лакхмир Чавла
Original Assignee
Дзе Джордж Вашингтон Юниверсити, Э Конгрешионэл Чартеред Нон-Фор-Профит Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691258(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дзе Джордж Вашингтон Юниверсити, Э Конгрешионэл Чартеред Нон-Фор-Профит Корпорейшн filed Critical Дзе Джордж Вашингтон Юниверсити, Э Конгрешионэл Чартеред Нон-Фор-Профит Корпорейшн
Publication of EA201691258A1 publication Critical patent/EA201691258A1/ru
Publication of EA037823B1 publication Critical patent/EA037823B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится, например, к способу, включающему введение субъекту, испытывающему интенсивный шок и получающему лечение катехоламином в дозе, эквивалентной по меньшей мере примерно 0,2 мкг/кг/мин норадреналина, дозы ангиотензина II, которая эффективна для повышения кровяного давления субъекта до уровня среднего артериального давления (САД) примерно 65 мм рт. ст. или выше и которая эффективна для снижения дозы катехоламина, необходимой для поддержания САД на уровне примерно 65 мм рт. ст., до дозы, эквивалентной примерно 0,05-2,0 мкг/кг/мин норадреналина или менее, или до дозы, эквивалентной примерно 0,05 мкг/кг/мин норадреналина или менее.
EA201691258A 2013-12-18 2014-12-18 Способ лечения субъекта, испытывающего интенсивный шок и получающего лечение катехоламином или вазопрессином EA037823B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US201461955706P 2014-03-19 2014-03-19
PCT/US2014/071186 WO2015095535A1 (en) 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension

Publications (2)

Publication Number Publication Date
EA201691258A1 true EA201691258A1 (ru) 2016-11-30
EA037823B1 EA037823B1 (ru) 2021-05-25

Family

ID=53367119

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691258A EA037823B1 (ru) 2013-12-18 2014-12-18 Способ лечения субъекта, испытывающего интенсивный шок и получающего лечение катехоламином или вазопрессином

Country Status (23)

Country Link
US (7) US9220745B2 (ru)
EP (2) EP2986308B1 (ru)
JP (3) JP6824739B2 (ru)
KR (3) KR20230051721A (ru)
CN (3) CN112546197A (ru)
AU (2) AU2014364528C1 (ru)
BR (1) BR112016013961A2 (ru)
CA (1) CA2933601A1 (ru)
CY (1) CY1122604T1 (ru)
DK (1) DK2986308T3 (ru)
EA (1) EA037823B1 (ru)
ES (1) ES2771749T3 (ru)
HR (1) HRP20200009T1 (ru)
HU (1) HUE047062T2 (ru)
IL (1) IL246162B (ru)
LT (1) LT2986308T (ru)
MX (2) MX2016008108A (ru)
NZ (1) NZ721089A (ru)
PL (1) PL2986308T3 (ru)
PT (1) PT2986308T (ru)
RS (1) RS59804B1 (ru)
SI (1) SI2986308T1 (ru)
WO (1) WO2015095535A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
ES2771749T3 (es) 2013-12-18 2020-07-07 The George Washington Univ A Congressionally Chartered Not For Profit Corporation Angiotensina II en combinación para el tratamiento de hipotensión
SG11201610897VA (en) * 2014-07-08 2017-01-27 Jolla Pharma Methods for treating hypotension
WO2016153558A1 (en) 2015-03-20 2016-09-29 Atkinson Arthur J Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
KR20180108630A (ko) * 2016-01-07 2018-10-04 라 졸라 파마슈티칼 컴파니 혈관수축제의 투여 방법
CA3010781A1 (en) 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
US11583568B2 (en) 2017-04-14 2023-02-21 La Jolla Pharma, Llc Methods for administering angiotensin II
TW201927331A (zh) * 2017-12-15 2019-07-16 美商拉荷亞製藥公司 血管收縮素組合物及與其相關之方法
WO2023244552A1 (en) * 2022-06-15 2023-12-21 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
WO2002098906A1 (en) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
JP2007510643A (ja) 2003-11-06 2007-04-26 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
EP1942985B1 (en) 2005-09-29 2011-04-27 Fibrogen, Inc. Methods for reducing blood pressure
AU2006332449B2 (en) * 2005-12-30 2008-05-15 Howard Florey Institute Of Experimental Physiology And Medicine A method of treatment
US20070293552A1 (en) 2006-06-15 2007-12-20 Gorczynski Richard J Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
BRPI0719319A2 (pt) 2006-11-17 2014-02-04 Da Volterra Liberação colônica usando contas de zn/pectina com um revestimento de eudragit
WO2009009907A1 (en) 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
EP2350649A4 (en) 2008-11-28 2012-11-14 Abbott Lab STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
US9572856B2 (en) * 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
KR20130026504A (ko) 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
EP3858437A1 (en) 2013-04-26 2021-08-04 La Jolla Pharma, LLC Compositions and methods for treating renal failure
ES2771749T3 (es) 2013-12-18 2020-07-07 The George Washington Univ A Congressionally Chartered Not For Profit Corporation Angiotensina II en combinación para el tratamiento de hipotensión
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
SG11201610897VA (en) 2014-07-08 2017-01-27 Jolla Pharma Methods for treating hypotension
KR20180108630A (ko) 2016-01-07 2018-10-04 라 졸라 파마슈티칼 컴파니 혈관수축제의 투여 방법
CA3010781A1 (en) 2016-01-07 2017-07-13 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
US11583568B2 (en) 2017-04-14 2023-02-21 La Jolla Pharma, Llc Methods for administering angiotensin II
TW201927331A (zh) 2017-12-15 2019-07-16 美商拉荷亞製藥公司 血管收縮素組合物及與其相關之方法

Also Published As

Publication number Publication date
EA037823B1 (ru) 2021-05-25
US20150164980A1 (en) 2015-06-18
AU2014364528A9 (en) 2016-07-28
US20190328827A1 (en) 2019-10-31
US20180193407A1 (en) 2018-07-12
DK2986308T3 (en) 2020-01-27
MX2016008108A (es) 2017-03-09
HUE047062T2 (hu) 2020-04-28
EP3607962A1 (en) 2020-02-12
EP2986308B1 (en) 2019-10-16
AU2020277230A1 (en) 2020-12-24
JP6824739B2 (ja) 2021-02-03
CA2933601A1 (en) 2015-06-25
JP2017501154A (ja) 2017-01-12
AU2014364528A1 (en) 2016-06-30
NZ721089A (en) 2022-10-28
BR112016013961A2 (pt) 2017-10-10
SI2986308T1 (sl) 2020-03-31
KR102399383B1 (ko) 2022-05-19
PL2986308T3 (pl) 2020-05-18
KR20160117437A (ko) 2016-10-10
US11096983B2 (en) 2021-08-24
PT2986308T (pt) 2020-01-21
CN106061493A (zh) 2016-10-26
US10765722B2 (en) 2020-09-08
CY1122604T1 (el) 2021-03-12
RS59804B1 (sr) 2020-02-28
AU2014364528B2 (en) 2020-08-27
US20220047669A1 (en) 2022-02-17
CN111920939A (zh) 2020-11-13
JP2022137224A (ja) 2022-09-21
US10493124B2 (en) 2019-12-03
US20160129072A1 (en) 2016-05-12
IL246162B (en) 2020-03-31
US9220745B2 (en) 2015-12-29
US20190070250A1 (en) 2019-03-07
KR20230051721A (ko) 2023-04-18
ES2771749T3 (es) 2020-07-07
EP2986308A1 (en) 2016-02-24
MX2020011190A (es) 2020-11-13
JP2019214610A (ja) 2019-12-19
WO2015095535A1 (en) 2015-06-25
CN112546197A (zh) 2021-03-26
US11559559B2 (en) 2023-01-24
WO2015095535A9 (en) 2016-07-14
JP7175506B2 (ja) 2022-11-21
EP2986308A4 (en) 2017-01-11
AU2014364528C1 (en) 2021-01-07
IL246162A0 (en) 2016-07-31
HRP20200009T1 (hr) 2020-03-20
US20230226141A1 (en) 2023-07-20
US10028995B2 (en) 2018-07-24
KR20220028125A (ko) 2022-03-08
LT2986308T (lt) 2020-03-25

Similar Documents

Publication Publication Date Title
EA201691258A1 (ru) Ангиотензин ii самостоятельно или в комбинации для лечения гипотензии
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
NZ774222A (en) Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201690212A8 (ru) Способы лечения или профилактики офтальмологических патологических состояний
BR112015022197A2 (pt) tratamento de cataplexia
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
WO2014107685A3 (en) Compositions and methods for using huperzine and analogs thereof
MX2018001684A (es) Metodo de curacion de heridas.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
EA201891533A1 (ru) Способы и композиции для лечения синдрома хантера
EA202092463A1 (ru) Ангиотензин ii самостоятельно или в комбинации для лечения гипотензии
MX2021001394A (es) Metodo para mejorar la eficacia de un agente anticanceroso.
EA202190751A1 (ru) Способы лечения миелопролиферативных расстройств
MX2016006256A (es) Tratamiento de glaucoma usando laquinimod.
EA201892389A1 (ru) Офтальмологическая композиция, содержащая синергическую комбинацию гликогена и гиалуроновой кислоты или ее соли
HK1216233A1 (zh) 含有四氫吡喃基氨基環戊基羰基四氫吡啶並吡啶衍生物作為有效成分的眼後段疾病的預防或治療劑
EA201200443A1 (ru) Комбинированное лекарственное средство и способ лечения венозных церебральных дисциркуляций
EA201991133A1 (ru) Способы лечения синдрома альпорта с использованием бардоксолон-метила или его аналогов
UA106472U (uk) Засіб для лікування дерматологічних захворювань